Cerity Partners
BCLI

Cerity Partners’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Cerity Partners’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-844
Closed -$49K – 537
2018
Q2 		$49K Hold
844
– – ﹤0.01% 532
2018
Q1 		$40K Buy
+844
New +$42.5K ﹤0.01% 518

Other funds holding BCLI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CPP
Crow Point Partners Boston, Massachusetts $64M AUM 33.5% 1-Year Est. Return

Cerity Partners's BCLI Position: Q3 2018 in Review

Cerity Partners sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2018, closing a stake of 844 shares — an estimated $49K sold.

Cerity Partners first reported a position in BCLI in Q1 2018 and held it in 2 quarters. The position peaked at $49K in Q2 2018. 37 funds tracked by Wall St. Rank hold BCLI as of Q3 2018.

  • Cerity Partners reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2018 after selling out during the quarter.
  • Cerity Partners sold 844 BRAINSTORM CELL THERAPUTC shares in Q3 2018, an estimated $49K.
  • Cerity Partners first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2018 and held it in 2 quarters.
  • Cerity Partners's BRAINSTORM CELL THERAPUTC position peaked at $49K in Q2 2018.
  • 37 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2018.

Based on Cerity Partners's 13F filing for Q3 2018, filed 15 Nov 2018.